CardieX Beheer

Beheer criteriumcontroles 3/4

De CEO CardieX is Craig Cooper, benoemd in Dec2017, heeft een ambtstermijn van 6.92 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 1.13M, bestaande uit 83.4% salaris en 16.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.21% van de aandelen van het bedrijf, ter waarde A$ 584.50K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 6.3 jaar.

Belangrijke informatie

Craig Cooper

Algemeen directeur

AU$1.1m

Totale compensatie

Percentage CEO-salaris	83.4%
Dienstverband CEO	6.9yrs
Eigendom CEO	2.2%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Craig Cooper's beloning veranderd ten opzichte van CardieX's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$1m	AU$946k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$8m
Dec 31 2023	n/a	n/a	-AU$9m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$1m	AU$772k	-AU$19m
Mar 31 2023	n/a	n/a	-AU$16m
Dec 31 2022	n/a	n/a	-AU$14m
Sep 30 2022	n/a	n/a	-AU$13m
Jun 30 2022	AU$1m	AU$608k	-AU$12m
Mar 31 2022	n/a	n/a	-AU$11m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$1m	AU$529k	-AU$5m
Mar 31 2021	n/a	n/a	-AU$4m
Dec 31 2020	n/a	n/a	-AU$3m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$911k	AU$447k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$851k	AU$419k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$392k	AU$226k	-AU$3m

Compensatie versus markt: De totale vergoeding ($USD 746.76K ) Craig } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 299.99K ).

Compensatie versus inkomsten: De vergoeding van Craig is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Craig Cooper (61 yo)

6.9yrs

Tenure

AU$1,134,097

Compensatie

Mr. Craig R. Cooper, BEc., LLB (Hons), is the Co-Owner at C2 Ventures Pty Ltd. He is Co-Founder, Group CEO, MD & Executive Director of CardieX Limited. He was Co-Founder, CEO, MD & Executive Director of Ca...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Niall Charles Cairns	Co-Founder & Executive Chairman	6.9yrs	AU$488.43k	0.66% A$ 174.4k
Craig Cooper	Co-Founder	6.9yrs	AU$1.13m	2.21% A$ 584.5k
Ahmad Qasem	Chief Science & Research Officer	no data	AU$240.19k	0.0084% A$ 2.2k
Douglas Kurschinski	Executive VP & Head of Global Sales for AtCor Medical Division	no data	AU$360.84k	geen gegevens
Mark Gorelick	Chief Product Officer	3.9yrs	AU$395.47k	0.038% A$ 9.9k
Catherine Liao	Chief Strategy Officer	2.2yrs	AU$385.31k	0% A$ 0
Sanjeev Bhavnani	Chief Clinical Officer	less than a year	geen gegevens	geen gegevens
Louisa Ho	Company Secretary	1.4yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Niall Charles Cairns	Co-Founder & Executive Chairman	6.9yrs	AU$488.43k	0.66% A$ 174.4k
Craig Cooper	Co-Founder	6.9yrs	AU$1.13m	2.21% A$ 584.5k
Randall Nelson	Independent Non-Executive Director	9yrs	AU$85.08k	0.0052% A$ 1.4k
Harry Kim	Special Advisor	5.7yrs	geen gegevens	geen gegevens
Alberto Avolio	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
John Cockcroft	Member of Medical Advisory Board	2.4yrs	geen gegevens	geen gegevens
Charlie Taylor	Independent Non-Executive Director	less than a year	AU$24.14k	geen gegevens

6.3yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

CardieX Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CardieX Limited, Annual General Meeting, Nov 29, 2024

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

Recent updates

New minor risk - Share price stability

CardieX Limited, Annual General Meeting, Nov 29, 2024

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.14 loss in FY 2023)

CardieX (ASX:CDX) Is Carrying A Fair Bit Of Debt

Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.14 loss in FY 2023)

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd